Home Shop Aclacinomycin A

Aclacinomycin A

BML-AW8655

Datasheet
Manual
SDS
CofA

Already have an account?

Originally identified as an anti-tumor drug, aclacinomycin A is the first described non-peptidic inhibitor showing discrete specificity for the chymotrypsin-like activity of the 20S proteasome. Aclacinomycin A has no effect on cathepsin B, it stimulates trypsin activity but inhibits the activity of both chymotrypsin and calpain.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

Product Details

Alternative Name	Aclarubicin
Appearance	Yellow powder with orange cast.
CAS	57576-44-0
Couple Target	Calpain, Chymotrypsin, Proteasome, Trypsin
Couple Type	Activator, Inhibitor
Formula	C₄₂H₅₃NO₁₅
MW	811.9
Purity	≥95% (TLC)
Solubility	Soluble in DMSO (25mg/ml) or dimethyl formamide (25mg/ml).

Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended.
Long Term Storage	-20°C
Shipping	Ambient Temperature

Regulatory Status	RUO – Research Use Only

Chemical-induced phase transition and global conformational reorganization of chromatin: Wang, T., Shi, S., et al.; Nat. Commun. 14, 5556 (2023), Abstract
Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib: C.W. Chen, et al.; Exp. Cell Res. 417, 113219 (2022), Abstract
Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2: Hekman, R. M., Hume, A. J., et al.; Mol. Cell 80, 1104 (2020), Abstract
Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency: Trobridge, G. D., Beard, B. C., et al.; PLoS One 7, e45173 (2012), Abstract
Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test: M. Lehmann, et al.; Environ. Mol. Mutagen. 43, 250 (2004), Abstract
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation: K. Saito, et al.; Int. J. Hematol. 71, 238 (2000), Abstract
The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome: M. E. Figueiroda-Pereira et al.; J. Biol. Chem. 271, 16455 (1996), Abstract
Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin: T. Isoe et al.; Biochim. Biophys. Acta. 1117, 131 (1992), Abstract

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Datasheet

Certificate of Analysis

Please enter the lot number as featured on the product label

Lot No. :

SDS

Enzo Life Science provides GHS Compliant SDS

If your language is not available please fill out the SDS request form

Your Cart

Your Cart

Aclacinomycin A

BML-AW8655

Product Details

Handling & Storage

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Certificate of Analysis

SDS

Change Country

Tell us about You

Tell us about your paper

Tell us about You

Tell us about your project